Detection and Quantitation of Soluble B7-H3 in Expressed Prostatic Secretions: A Novel Marker in Patients With Chronic Prostatitis

No AccessJournal of UrologyAdult Urology1 Feb 2011Detection and Quantitation of Soluble B7-H3 in Expressed Prostatic Secretions: A Novel Marker in Patients With Chronic Prostatitis Xuedong Wei, Guangbo Zhang, Hexing Yuan, Xiang Ding, Shuxiang Li, Xueguang Zhang, and Jianquan Hou Xuedong WeiXuedong Wei Department of Urology, Suzhou, People's Republic of China , Guangbo ZhangGuangbo Zhang Clinical Immunology Laboratory, Suzhou, People's Republic of China , Hexing YuanHexing Yuan Department of Urology, Suzhou, People's Republic of China , Xiang DingXiang Ding Department of Urology, Suzhou, People's Republic of China , Shuxiang LiShuxiang Li Institute of Medical Biotechnology, Soochow University, Suzhou, People's Republic of China , Xueguang ZhangXueguang Zhang Institute of Medical Biotechnology, Soochow University, Suzhou, People's Republic of China , and Jianquan HouJianquan Hou First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China View All Author Informationhttps://doi.org/10.1016/j.juro.2010.09.104AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We determined the soluble B7-H3 level and its clinical significance in serum and expressed prostatic secretions of patients with chronic prostatitis, including chronic bacterial prostatitis (type II) and chronic pelvic pain syndrome. Materials and Methods: Using enzyme-linked immunosorbent assay we measured soluble B7-H3 in 11 patients with chronic prostatitis (type II), and 26 with inflammatory (type IIIA) and 54 with noninflammatory (type IIIB) chronic pelvic pain syndrome, and healthy donors. We assessed differences between these groups using Student's t test. As determined by the National Institutes of Health-Chronic Prostatitis Symptom Index, we correlated soluble B7-H3 with clinical pain using the Pearson test. Results: We found no significant difference between serum soluble B7-H3 in healthy donors and patients with chronic prostatitis (p = 0.897). However, soluble B7-H3 in expressed prostatic secretions was statistically significantly decreased in patients with chronic prostatitis vs controls (p <0.001). ROC using soluble B7-H3 greater than 38.82 ng/ml in expressed prostatic secretions distinguished patients with chronic prostatitis from healthy donors with 90.9% sensitivity and 83.5% specificity. Also, soluble B7-H3 levels in expressed prostatic secretions correlated negatively with the Chronic Prostatitis Symptom Index and the pain subscore. Compared to the pretreatment level soluble B7-H3 in expressed prostatic secretions was significantly increased in patients with a greater than 25% decrease in the Chronic Prostatitis Symptom Index total score (p = 0.016). Conclusions: Data indicate that the soluble B7-H3 level in expressed prostatic secretions is a novel chronic prostatitis marker that correlates negatively with subjective symptoms. References 1 : Epidemiology of prostatitis: new evidence for a world-wide problem. World J Urol2003; 21: 70. Google Scholar 2 : Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology2000; 56: 1025. Crossref, Medline, Google Scholar 3 : Interleukin-8 levels in seminal plasma in chronic prostatitis/chronic pelvic pain syndrome and nonspecific urethritis. BJU Int2006; 97: 1043. Google Scholar 4 : Interleukin-10 levels in seminal plasma: implications for chronic prostatitis-chronic pelvic pain syndrome. J Urol2002; 167: 753. Link, Google Scholar 5 : Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol2004; 172: 839. Link, Google Scholar 6 : IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. J Urol2000; 164: 214. Link, Google Scholar 7 : Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol1979; 121: 755. Link, Google Scholar 8 : Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins. Urology1997; 50: 893. Google Scholar 9 : B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol2001; 2: 269. Google Scholar 10 : Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics2003; 82: 365. Google Scholar 11 : Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology2008; 123: 538. Google Scholar 12 : Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol1968; 5: 492. Google Scholar 13 : A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol2009; 56: 544. Google Scholar 14 : Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World J Urol2006; 24: 55. Google Scholar 15 : Anti-nanobacterial therapy for men with chronic prostatitis/chronic pelvic pain syndrome and prostatic stones: preliminary experience. J Urol2005; 173: 474. Link, Google Scholar 16 : A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol2003; 169: 1401. Link, Google Scholar 17 : Time-course study of cellular immune response and testosterone metabolism in an autoimmune model for chronic prostatic inflammation. J Urol1998; 160: 1546. Link, Google Scholar 18 : Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha as possible biomarkers for the chronic pelvic pain syndrome. J Urol2008; 179: 1857. Link, Google Scholar 19 : Characterization of mouse and human B7-H3 genes. J Immunol2002; 168: 6294. Google Scholar 20 : The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization. Proc Natl Acad Sci USA2004; 101: 12969. Google Scholar 21 : Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol2004; 172: 2352. Google Scholar 22 : Characterization and application of two novel monoclonal antibodies against 2IgB7-H3: expression analysis of 2IgB7-H3 on dendritic cells and tumor cells. Tissue Antigens2005; 66: 83. Google Scholar 23 : B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol2004; 173: 5445. Google Scholar 24 : An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo. J Gastrointest Surg2006; 10: 635. Google Scholar 25 : Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA2004; 101: 12640. Google Scholar 26 : The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol2003; 4: 899. Google Scholar 27 : Murine B7-H3 is a negative regulator of T cells. J Immunol2004; 173: 2500. Google Scholar 28 : B7-H3 regulates the development of experimental allergic conjunctivitis in mice. Immunol Lett2007; 113: 52. Google Scholar 29 : B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA2007; 104: 19458. Google Scholar 30 : B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res2007; 67: 7893. Google Scholar © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 2February 2011Page: 532-537 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.Keywordscytokinesprostatepainbiological markersprostatitisMetricsAuthor Information Xuedong Wei Department of Urology, Suzhou, People's Republic of China Equal study contribution. More articles by this author Guangbo Zhang Clinical Immunology Laboratory, Suzhou, People's Republic of China Equal study contribution. More articles by this author Hexing Yuan Department of Urology, Suzhou, People's Republic of China More articles by this author Xiang Ding Department of Urology, Suzhou, People's Republic of China More articles by this author Shuxiang Li Institute of Medical Biotechnology, Soochow University, Suzhou, People's Republic of China More articles by this author Xueguang Zhang Institute of Medical Biotechnology, Soochow University, Suzhou, People's Republic of China More articles by this author Jianquan Hou First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China Equal study contribution. More articles by this author Expand All Advertisement PDF downloadLoading ...